Advertisement

Rabbit Monoclonal Antibodies

  • Weimin ZhuEmail author
  • Aihua Li
  • Taiying Chen
Chapter

Abstract

Rabbit monoclonal antibodies are relatively new in the immunohistochemistry (IHC) field. The majority of rabbit monoclonal antibodies are developed using a patented and proprietary rabbit hybridoma technology—the RabMAb® hybridoma technology. RabMAb primary antibodies offer greater advantages over classic mouse monoclonal antibodies, providing higher binding affinity, more diversified antigenic epitope recognition and a highly stable IgG structure. Since the inception of this technology in early 2000s, RabMAb primary antibodies have quickly replaced mouse monoclonal antibodies for several important markers such as HER2, c-kit/CD117, estrogen receptor and progesterone receptor in the pathology IHC field. RabMAb primary antibodies improve the effectiveness of certain markers that have been especially difficult in pathology IHC such as ERG, c-myc, bcl-2, MSH-6, MSH2 and PMS2. Because RabMAb primary antibodies offer superior sensitivity and specificity, performance reliability, as well as easy adaption to current automated stainers, it is clear that this group of antibodies is becoming the preferred choice for performing IHC in pathology laboratories.

Keywords

Rabbit monoclonal antibodies hybridoma RabMAb® RabMAb primary antibodies Immunohistochemistry Diagnostic markers Prognostic markers Companion diagnostics Sensitivity Specificity Stability Reliability ER PR HER2 c-MYC ERG bcl-2 MSH6 MSH2 PMS2 CD117 (c-kit) PD1 PDL1 

Abbreviations

RabMAb®

Rabbit monoclonal antibody developed using a patented and Epitomics’ proprietary rabbit hybridoma technology

References

  1. 1.
    Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA. 1995;92(20):9348–52.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Zhu W, Yu GL. Rabbit hybridoma. In: Andrew Z, editor. Therapeutic monoclonal antibodies: from bench to clinic. Hoboken, NJ: Wiley; 2009. p. 151–68.CrossRefGoogle Scholar
  3. 3.
    Mage RG, Lanning D, Knight KL. B cell and antibody repertoire development in rabbits: the requirement of gut-associated lymphoid tissues. Dev Comp Immunol. 2006;30(1–2):137–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Rossi S, Laurino L, Furlanetto A, et al. “Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Pathol. 2005;124(2):295–302.Google Scholar
  5. 5.
    Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7(12):929–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Huang Z, Zhu W, Szekeres G, Xia H. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2005;13(1):91–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12(7):590–8.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011;24(7):917–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Williams AR, Piris J, Wyllie AH. Immunohistochemical demonstration of altered intracellular localization of c-MYC oncogene production in human colorectal neoplasms. J Pathol. 1990;160(4):287–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012;7(4):e33813.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–9.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Nordic Immunohistocchemical Quality Control. http://www.nordiqc.org/Run-32-B11/Assessment/assessment-32-MSH6.htm. Accessed 22 May 2014.
  13. 13.
    Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov. 2013;12(7):489–92.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.SVP, Antibody Technology, AbcamBurlingameUSA
  2. 2.In Vitro Diagnostics, Epitomics – An Abcam® CompanyBurlingameUSA

Personalised recommendations